Phase 2 Bladder Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are 18 years old or older at the time of signing the consent form
- You have willingly given written consent to take part after the study has been fully explained to you
- A specialist lab has confirmed you have a specific type of high-grade bladder condition called non-muscle invasive carcinoma in situ (CIS), which may also involve certain early-stage bladder changes (confirm with trial site)
- You have either never received BCG treatment (a common bladder cancer therapy), OR you had BCG treatment but not within the last 24 months before your most recent diagnosis — OR you have a form of the condition that has stopped responding to BCG treatment (confirm with trial site)
Who may not be able to join:
- You have a penicillin allergy — though if your allergy history is uncertain, a blood test may be done to check (confirm with trial site)
- A specialist lab has confirmed you have a particular variation in the type of cells involved in your condition (confirm with trial site)
- Your condition also involves the prostate or the tubes that connect the kidneys to the bladder, based on your doctor's assessment
- You have ever had cancer that spread to the lymph nodes or other parts of the body, at any point in your life
- You have ever had a more advanced stage of bladder cancer (stage T2 or higher) at any point in your life
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Chief Scientific Operations Officer, Protara Therapeutics
Phone: 16468440337
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Cohort A and B: Incidence of high-grade Complete Response at any time according to central pathology after treatment with TARA-002
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.